rs104893668
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_003896.4(ST3GAL5):c.862C>T(p.Arg288*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000285 in 1,613,942 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_003896.4 stop_gained
Scores
Clinical Significance
Conservation
Publications
- GM3 synthase deficiencyInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: ClinGen, G2P, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes  0.0000197  AC: 3AN: 152060Hom.:  0  Cov.: 32 show subpopulations 
GnomAD2 exomes  AF:  0.0000239  AC: 6AN: 251258 AF XY:  0.00   show subpopulations 
GnomAD4 exome  AF:  0.0000294  AC: 43AN: 1461882Hom.:  0  Cov.: 31 AF XY:  0.0000220  AC XY: 16AN XY: 727246 show subpopulations 
Age Distribution
GnomAD4 genome  0.0000197  AC: 3AN: 152060Hom.:  0  Cov.: 32 AF XY:  0.0000269  AC XY: 2AN XY: 74272 show subpopulations 
Age Distribution
ClinVar
Submissions by phenotype
GM3 synthase deficiency    Pathogenic:5 
This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. This variant has been previously reported as disease-causing [PMID 15502825, 22990144, 28726809, 23436467, 25525159] -
This sequence change creates a premature translational stop signal (p.Arg288*) in the ST3GAL5 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ST3GAL5 are known to be pathogenic (PMID: 15502825, 22990144, 27232954). This variant is present in population databases (rs104893668, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with early-onset epilepsy syndrome and ganglioside GM3 synthase deficiency (PMID: 15502825, 22990144, 23436467). It has also been observed to segregate with disease in related individuals. This variant is also known as c.694C>T, p.R232X. ClinVar contains an entry for this variant (Variation ID: 5556). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
- -
- -
- -
not provided    Pathogenic:1 
Published functional studies demonstrate damage to ST3GAL5 function (Indellicato et al., 2019); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 29747824, 27232954, 30691927, 26649472, 28709807, 23436467, 22990144, 25525159, 15502825, 28726809, 30185102, 30209782, 31028937, 25131622, 31589614, 30576498) -
ST3GAL5-related disorder    Pathogenic:1 
The ST3GAL5 c.862C>T variant is predicted to result in premature protein termination (p.Arg288*). This variant has been reported in the homozygous state in multiple individuals with GM3 synthase deficiency (see for example, Fragaki et al. 2012. PubMed ID: 22990144; Table 1, Wang et al. 2013. PubMed ID: 23436467; Table 1, Gordon-Lipkin et al. 2018. PubMed ID: 30185102). This variant is reported in 0.0054% of alleles in individuals of European (non-Finnish) descent in gnomAD and it has been described as a founder variant in various Old Order Amish populations (Simpson et al. 2004. PubMed ID: 15502825; Bowser et al. 2019. PubMed ID: 30691927). An in vitro experimental study suggests this variant abolishes protein enzyme activity (Figure 3, Indellicato et al. 2019. PubMed ID: 30576498). Nonsense variants in ST3GAL5 are expected to be pathogenic. This variant is interpreted as pathogenic. -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at